Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.

eLife - 5 Jun 2015

Unni Arun M, Lockwood William W, Zejnullahu Kreshnik, Lee-Lin Shih-Queen, Varmus Harold

Abstract excerpt

Human lung adenocarcinomas (LUAD) contain mutations in EGFR in ∼15% of cases and in KRAS in ∼30%, yet no individual adenocarcinoma appears to carry activating mutations in both genes, a finding we have confirmed by re-analysis of data from over 600 LUAD. Here we provide evidence that co-occurrence of mutations in these two genes is deleterious. In transgenic mice programmed to express both mutant oncogenes in the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mice, Transgenic

Share to Mutant Proteins

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 26047463
DOI: 10.7554/eLife.06907
PMCID: PMC4478584

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.PMID 26047463Read ↗

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?Semantic proximity Read ↗

How Cancer Genomics Drives Cancer Biology: Does Synthetic Lethality Explain Mutually Exclusive Oncogenic Mutations?Semantic proximity Read ↗

Combinatorial Inactivation of Tumor Suppressors Efficiently Initiates Lung Adenocarcinoma with Therapeutic Vulnerabilities.Semantic proximity Read ↗

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilitiesSemantic proximity Read ↗

In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.Semantic proximity Read ↗

What makes oncogenes mutually exclusive?Semantic proximity Read ↗

Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.Semantic proximity Read ↗

Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.Semantic proximity Read ↗

A Functional Taxonomy of Tumor Suppression in Oncogenic KRAS–Driven Lung CancerSemantic proximity Read ↗

Transgenic oncogenes induce oncogene-independent cancers with individual karyotypes and phenotypes.Semantic proximity Read ↗

KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.Semantic proximity Read ↗

Hyperactivation of extracellular signal-regulated kinase (ERK) by RAS-mediated signaling or inhibition of dual specificity phosphatase 6 (DUSP6) is associated with toxicity in lung adenocarcinoma cells with mutations in <i>KRAS</i> or <i>EGFR</i>Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.